Everyone is at risk for glaucoma. Early diagnosis is the first step in preserving your patients' vision.
According to the World Health Organization, it is estimated that 4.5 million people globally are blind due to glaucoma. It is estimated that this number will rise to 11.2 million people by 2020.1 That’s a 149% increase—6.7 million more people who may be at risk of losing their vision to this "silent blinding disease", and they have no idea it's even happening. We can help them. Together, let's provide educational resources about glaucoma, its causes and risk factors, and share simple steps that can be taken to proactively preserve one's vision.
Estimates put the total number of suspected cases of glaucoma at over 60-million worldwide.2
Glaucoma is the second leading cause of blindness in the world.3
You are six times more likely to get glaucoma if you are over 60 years old.4
It is estimated that up to 50% of people with glaucoma don't realize they have it.5
Glaucoma is a group of eye diseases that damages the optic nerve. Optic nerve damage is caused by increased pressure from fluid that builds up inside the eye. Glaucoma affects peripheral (or side) vision, narrowing the field of view. Left untreated, glaucoma can cause total vision loss. Glaucoma can affect one or both eyes.
The National Eye Institute offers health and community professionals a glaucoma toolkit perfect for building glaucoma awareness. Materials for speakers and participants are available in English and Spanish and include:
- PowerPoint presentation
- Introduction to glaucoma
- Speakers guide
- Promotional announcement
- Glaucoma Eye-Q test
- Glaucoma fact sheet
- Tips for talking to your doctor
Take a proactive approach to preventing vision damage caused by glaucoma by scheduling regular vision screenings. That is every two to four years for patients under 40 years old and more frequently with age. High-risk patients should be tested every year or two after age 35. And, after age 65, eye exams should be scheduled every six months to a year.
A comprehensive screening for glaucoma includes checking for five factors before making a diagnosis:
- The inner eye pressure
- The shape and color of the optic nerve
- The complete field of vision
- The angle in the eye where the iris meets the cornea
- The thickness of the cornea
Share this video to help your patients understand how glaucoma is detected through a dilated eye exam.
Courtesy: National Eye Institute, National Institutes of Health (NEI/NIH)
In this webinar, Dr. Mark Dunbar, OD, FAAO, discusses how valuable CIRRUSTM HD-OCT from ZEISS has been in the early diagnosis and management of glaucoma in his cases using the guided progression analysis tool.
With today’s Optical Coherence Tomography (OCT) capabilities OCT has emerged as a crucial technique in investigating glaucomatous disease. With OCT’s retinal imaging capability and quantitative approach that can also be applied to the optic nerve, all parts of the eye that are potentially affected in glaucoma have become accessible with OCT. By obtaining quantitative data from glaucomatous eyes and comparing these with normal controls, the existence of glaucoma can be confirmed and the severity assessed during follow-up. Read Professor Jean-Philippe Nordmann's informative book OCT & Optic Nerve to find out more.
Complete the form below to request a free digital copy.
Please tell us a little about you. As a thanks, we'll email you a digital copy of OCT & Optic Nerve.
By using a complete line of ZEISS imaging technologies including the gold standard of perimetry, OCT Angiography and True Color ultra-widefield Fundus Imaging, clinicians have the advantage of being able to easily monitor change progression with the glaucoma workplace--integrated software that combines data sets from each technology into a single visualization.
Reaching new heights with the gold standard of perimetry, the HFA3 with Liquid Trial LensTM, SmartTouch and Guided Progression AnalysisTM (GPATM), plus SITA Faster, provides a streamlined and faster workflow.
ZEISS CIRRUS OCT with AngioPlex allows for the visualization of both vascular and structural information from a single, non-invasive scan, making visualization of microvasculature of the retina a routine part of everyday care.
Our next generation HD ultra-widefield fundus imaging from ZEISS is the first system to provide true color and clarity in an ultra-wide field of view—from the posterior pole to the far periphery.
The ZEISS Glaucoma Workplace is a fully interactive multimodality software solution that combines exam data from your OCT and fundus camera across three visits to better visualize change progression.
We want to keep you in the know about ZEISS products and events, as well as provide you useful and informative resources to benefit your practice and patients. Tell us more about you to make sure we send only the content that matters to you.
1 http://www.health.gov.tt/news/newsitem.aspx?id=334; referencing the World Health Organization (WHO)
2, 3 Glaucoma Research Foundation, Glaucoma Facts & Stats; https://www.glaucoma.org/glaucoma/glaucoma-facts-and-stats.php
4 Glaucoma Research Foundation, Are you at risk for glaucoma?; https://www.glaucoma.org/glaucoma/are-you-at-risk-for-glaucoma.php
5 National Eye Health Education Program (NEHEP), Learn About Glaucoma; https://nei.nih.gov/nehep/programs/glaucoma/learn-about